Navigation Links
Dr. Inder Verma named recipient of 2008 Vilcek Prize in biomedical science

New York, February 6, 2008 - The Vilcek Foundation has announced the names of the recipients of its annual prizes in biomedical research and in the arts. Dr. Inder Verma is the prize recipient for biomedical science; the prize recipient for the arts is composer Osvaldo Golijov. The Vilcek Foundation Prizes are awarded annually to foreign-born individuals for extraordinary contributions to society in the United States.

In explaining the motivation for the awards, Dr. Jan T. Vilcek, President of The Vilcek Foundation said, We should not have to be reminded of how much America owes to people who were born abroad, but we do. Historically, the United States has innumerable foreign-born individuals to thank for establishing it as a leader in the sciences and arts, and in many other fields as well. In awarding The Vilcek Foundation Prizes, our primary objective is to raise awareness of that reality. We should not forget that so much of what this country takes credit for is the achievement of immigrants.

Marica Vilcek, Vice-President of the Foundation, added: As the only foundation to recognize the outstanding contributions of foreign-born individuals to the biomedical sciences and the arts, we are in a privileged position to shine a spotlight on leaders such as Dr. Verma and Mr. Golijov, whose achievements we are pleased to honor this year.

A $50,000 cash award and a commemorative trophy created by designer Stefan Sagmeister will be presented to Dr. Verma and Mr. Golijov during The Foundations third annual awards dinner on Wednesday, March 26, 2008 at the Mandarin Oriental Hotel in New York. The two prize winners were chosen by independent panels of experts.

About the Prize Recipient

Dr. Inder M. Verma is an American Cancer Society Professor of Molecular Biology in the Laboratory of Genetics at The Salk Institute in La Jolla, California and one of the world's leading authorities on the development and use of engineered viruses for gene therapy. Dr. Verma was born in India, received a master's degree from Lucknow University, and a Ph.D. from The Weizmann Institute of Science in Rehovoth, Israel. After postdoctoral study at MIT in the laboratory of the Nobel laureate David Baltimore, he joined the faculty of The Salk Institute at age 26.

Dr. Vermas major research interests are cellular genes whose alteration can cause cancer and the development of techniques for gene therapy. Dr. Vermas group created a vector, or carrier, that is now used worldwide for gene delivery. The genetically engineered virus is used to insert new genes into cells in a test tube; the cells can then be returned to the body, where they produce an essential protein that the body is missing. Dr. Verma's group is also studying two genes implicated in familial breast cancer, BRCA1 and BRCA2, and recently demonstrated that their action is linked to the cell's division cycle and that BRCA1 regulates gene activity.

When the field of biotechnology was in its infancy, the Government of India invited Dr. Verma to join a task force charged with the goal to position the country as a leader in biotechnology. Dr. Verma has traveled to India every year for the past 37 years; he has lectured there on the topic of gene therapy, visited many institutions and advised a number of colleagues, young investigators and students.

For his many outstanding accomplishments, Dr. Verma was elected to the U.S. National Academy of Sciences and as a Foreign Fellow to the National Academy of Sciences, India. Dr. Verma was also elected to the Third World Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and the American Philosophical Society.


Contact: Sharu Williams
The Vilcek Foundation

Related medicine news :

1. A Reminder to Parents: Early Dental Visits Essential to Childrens Health
2. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
3. Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting
4. Asthma Foundation Offers National Flu Shot Finder
5. Health Insurance Finders Debuts A Comprehensive Guide to Family Health Insurance
6. FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia
7. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
8. Smilebox and Lifetime Television Promote Breast Cancer Awareness With Multimedia Designs for Sending Mammogram Reminders and Celebrating Courage
9. PartsSource Awarded US Patent for PartsFinder(TM) Application
10. Research says doctors gender may hinder early diagnosis of heart disease in women
11. Launches Video Contest for Young Directors
Post Your Comments:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: